Royal London Asset Management Ltd. Increases Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Royal London Asset Management Ltd. grew its holdings in Becton, Dickinson and Company (NYSE:BDXFree Report) by 1.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 112,503 shares of the medical instruments supplier’s stock after purchasing an additional 1,897 shares during the quarter. Royal London Asset Management Ltd.’s holdings in Becton, Dickinson and Company were worth $29,090,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in BDX. Moneta Group Investment Advisors LLC boosted its stake in shares of Becton, Dickinson and Company by 95,813.8% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 4,045,643 shares of the medical instruments supplier’s stock valued at $1,028,807,000 after purchasing an additional 4,041,425 shares during the period. Norges Bank purchased a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at approximately $697,398,000. Osaic Holdings Inc. boosted its stake in shares of Becton, Dickinson and Company by 1,353.9% in the second quarter. Osaic Holdings Inc. now owns 1,680,292 shares of the medical instruments supplier’s stock valued at $31,207,000 after purchasing an additional 1,564,723 shares during the period. Ontario Teachers Pension Plan Board boosted its stake in shares of Becton, Dickinson and Company by 242.8% in the third quarter. Ontario Teachers Pension Plan Board now owns 1,783,769 shares of the medical instruments supplier’s stock valued at $461,158,000 after purchasing an additional 1,263,391 shares during the period. Finally, PineStone Asset Management Inc. lifted its stake in Becton, Dickinson and Company by 262.0% in the third quarter. PineStone Asset Management Inc. now owns 847,448 shares of the medical instruments supplier’s stock worth $219,091,000 after acquiring an additional 613,369 shares during the last quarter. Hedge funds and other institutional investors own 86.72% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on BDX shares. Raymond James lifted their price target on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. TheStreet downgraded shares of Becton, Dickinson and Company from a “b” rating to a “c+” rating in a research note on Thursday, November 9th. Barclays lifted their price target on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a research note on Monday, February 5th. Piper Sandler decreased their price target on shares of Becton, Dickinson and Company from $305.00 to $280.00 and set an “overweight” rating for the company in a research note on Friday, November 10th. Finally, Morgan Stanley decreased their price target on shares of Becton, Dickinson and Company from $310.00 to $280.00 and set an “overweight” rating for the company in a research note on Monday, December 4th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Becton, Dickinson and Company has an average rating of “Moderate Buy” and an average target price of $279.17.

Check Out Our Latest Stock Report on BDX

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $237.62 on Friday. The firm’s fifty day simple moving average is $239.11 and its 200-day simple moving average is $248.74. The stock has a market capitalization of $68.65 billion, a price-to-earnings ratio of 56.31, a PEG ratio of 1.95 and a beta of 0.42. Becton, Dickinson and Company has a 12 month low of $228.62 and a 12 month high of $287.32. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.08 and a quick ratio of 0.64.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last announced its earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 EPS for the quarter, beating analysts’ consensus estimates of $2.39 by $0.29. The business had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.73 billion. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The company’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the company posted $2.98 EPS. As a group, equities analysts forecast that Becton, Dickinson and Company will post 12.94 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 29th. Stockholders of record on Friday, March 8th will be issued a $0.95 dividend. The ex-dividend date is Thursday, March 7th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.60%. Becton, Dickinson and Company’s payout ratio is 90.05%.

Becton, Dickinson and Company Profile

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Featured Stories

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.